DBV Pulls EU Peanut Allergy Patch Filing To Work On A Stronger Application

Following regulatory setbacks in the US and also now in the EU, DBV Technologies is to conduct a new pivotal trial of a modified version of its peanut allergy patch to support its efforts to win marketing approval.

Peanut allergy. Conceptual image.
DBV's patch is for treating peanut allergy in children • Source: Alamy

DBV Technologies has withdrawn its EU marketing authorization application (MAA) for Viaskin Peanut (Arachis hypogaea extract), an investigational patch for peanut allergy in children that was rejected for marketing in the US in 2020.

The company withdrew the MAA after learning from the European Medicines Agency that the trial data it used in the...

More from Product Reviews

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.